Sanofi

Leland Stanford Junior University

Pieris Pharmaceuticals Gmbh

Ingo Focken

Christian Lange

Jochen Kruip

Ercole Rao

Carsten Corvey

Thomas Langer

Katja Kroll

Francis Blanche

Christine Rothe

Andrea Allersdorfer

Marlon Hinner

Beatrice Cameron

Alexander Wiedenmann

Vincent Mikol

Kristian Hobolt Jensen

Christian Beil

Tarik Dabdoubi

Martin Lorenz

Nicolas Baurin

Bradley Lunde

Christian Engel

Laurent Fraisse

Martin Hülsmeyer

Astrid Rey

Michael Mourez

Heike Stump

Mathias Gebauer

Peter Wonerow

Dorothea Rat

Susanta K Sarkar

Thomas Stuedemann

Peter Florian

Juergen Schaefer

Bernard Calandra

Gerhard Zoller

Sanjiv Sam Gambhir

Gerhard Hessler

Béatrice Cameron

Hans-Falk Rasser

Wulf-Dirk Leuschner

Guido Haschke

Richard H Kimura

Dieter Schmoll

Arutselvan Natarajan

Sandra Weil

Marco Mueller

Nadja Spindler

Soraya Hoelper

Ohad Ilovich

Garima Tiwari

Jennifer Jung

Marta Amaral

Marco MÜLLER

Binding proteins comprising a VL region paired with a VH region, and a CH1 region paired with a CL region, wherein the VL region and VH region comprise opposite charged mutations to facilitate pairing, and wherein the CH1 region and CL region comprise mutations to facilitate pairing, are provided. Binding proteins comprising one or more cysteine residues engineered into the VH/VL pair to form one or more disulfide bonds, are also provided. Multispecific binding proteins, nucleic acids encoding binding proteins and multispecific binding proteins, expression vectors, host cells, pharmaceutical composition and methods of treatment administering the binding proteins or multispecific binding proteins described herein are also provided.

Multispecific binding proteins with mutant fab domains

Provided herein are multispecific antibodies, e.g. bispecific antibodies, which are modified such that the desired chain pairing takes place and/or can be selected for. Specifically, this is achieved by using different dimerization domains for light chain pairing. Also disclosed herein are nucleic acids encoding for these antibodies, expression vectors comprising these nucleic acids, cells expressing them, and further to pharmaceutical compositions comprising the antibodies, as well as methods of isolating the antibodies.

Multispecific antibodies facilitating selective light chain pairing

The present invention relates to fusion molecules that have binding specificity for pyoverdine type I, II and III and pyochelin and can be used in various applications, including diagnostic and/or therapeutic applications, for example, to inhibit or reduce growth ofand/or to prevent or treatbiofilm infection as well as diseases or disorders associated withbiofilm infection. The present invention also concerns methods of producing the fusion molecules described herein as well as compositions and kits comprising such fusion molecules. The present invention further relates to nucleic acid molecules encoding the fusion molecules described herein.

Fusion molecules

The invention relates to a companion diagnostic antibody-like binding protein based on the humanized monoclonal antibody, DS6, to be used as diagnostic tool for in vivo detection and quantification of the tumor-associated MUC1-sialoglycotope, CA6.

Immuno imaging agent for use with antibody-drug conjugate therapy

The present invention discloses novel antibodies that specifically bind to the human platelet membrane protein Glycoprotein VI (GPVI) and their monovalent fragments or derivatives. The antibodies of the invention are antibodies from hybridoma clone 390 and fragment antibodies thereof able to induce a GPVI depletion phenotype. These antibodies and Fab fragments are able to block collagen binding and thus preventing platelet activation by collagen. The invention also relates to hybridoma clones and expression plasmids for the production of disclosed antibodies and Fab fragments. The present invention further refers to the uses of monovalent antibody fragments to manufacture research, diagnostic and immunotherapeutic agents for the treatment of thrombosis and other vascular diseases. The invention also concerns a Fab bearing a molecule at the C-terminal extremity, as well as method for prevention of recognition of Fab by antibodies using such modified Fab. The invention concerns a method for prevention of platelet activation when an anti-GP VI Fab is used.

Antagonist antibodies and their fab fragments against GPVI and uses thereof

Heterocyclic derivatives, processes for their preparation, medicaments comprising these compounds, and the use thereof. The invention relates to compounds of the formula I in which the radicals R1, R2, R3, R4, W, A, B, D, E, G, L, M, R, T and Y have the stated meanings, and to the physiologically tolerated salts thereof. The compounds are suitable for example for the treatment of the metabolic syndrome, insulin resistance, obesity and diabetes. 

Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof

Growing community of inventors

Hocheim, Germany

Ingo Focken